Under this partnership, EVA Pharma to import, market, promote and distribute BeiGene’s flagship Oncology medicines BRUKINSA and TEVIMBRA in Egypt. 
 

DUBAI, CAIRO, Egypt - 27^th March 2025 – EVA Pharma,  one of the fastest-growing healthcare organizations in the Middle East and Africa, and BeiGene International GmbH (an affiliate of BeiGene Ltd., NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd, have announced a strategic partnership to expand treatment options for cancer patients in Egypt.  
 

Under the terms of the agreement, EVA Pharma will begin by launching BRUKINSA (zanubrutinib), a second-generation Bruton Tyrosine Kinase (BTK) inhibitor. Another medicine to be introduced under this partnership is TEVIMBRA (tislelizumab), an immunotherapy that targets the PD-1 pathway. According to the U.S. Food and Drug Administration (FDA), BRUKINSA is approved for the treatment of certain blood cancers, while TEVIMBRA is approved for the treatment of solid tumors.^,1,2 

 

“At BeiGene, our mission is to expand access to innovative oncology treatments for patients worldwide. This partnership with EVA Pharma is a significant step toward achieving that goal in Egypt. 

 

By combining BeiGene’s advanced therapies, such as BRUKINSA and TEVIMBRA, with EVA Pharma’s strong regional expertise, we are forming a powerful alliance to meet the urgent needs of cancer patients. Together, we are not only delivering hope but also working to raise the standard of cancer care in Egypt and across the region,” said Mohammed Al Kapany, General Manager of BeiGene’s Middle East and Africa (MENA) region. 

 

“We are eager to provide cancer patients with innovative and accessible therapies. That’s why we are partnering with BeiGene — to improve patient outcomes by increasing access to critical treatments. It is also worth noting that this marks the third global pharmaceutical company to choose EVA Pharma as a partner of choice, a reflection of the trust and credibility we have built over the years,” said Dr. Amgad Talaat, Strategic Alliances Director and Saudi Arabia Cluster Head, EVA Pharma. 

 

The Global Cancer Observatory (GLOBOCAN 2022) reports over 366,000 cancer cases in Egypt, with nearly 95,300 cancer-related deaths.³ This partnership was established to address the significant unmet need for advanced oncology treatments in Egypt, reflecting the shared commitment of EVA Pharma and BeiGene to expand access to innovative cancer care. 

 

It also represents a major milestone in improving access to these innovative therapies across the region. 

 

Under the agreement, EVA Pharma will lead the importation, marketing, and medical promotion of BeiGene’s oncology therapies in Egypt — treatments that have shown meaningful progress in advancing cancer care. By leveraging EVA Pharma’s deep expertise in distribution, medical affairs,  

and regional market dynamics, this collaboration aims to make these innovative options more accessible to patients in Egypt. 

 

EVA Pharma and BeiGene are also committed to supporting healthcare professionals through ongoing medical education and resources to help optimize patient outcomes. This partnership represents a significant step toward strengthening cancer care in Egypt and contributing to broader efforts to reduce the global cancer burden — delivering renewed hope to patients and their families. 

 

About TEVIMBRA®(tislelizumab) 

 

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping the body’s immune cells detect and fight tumors. 

TEVIMBRA is the foundational asset of BeiGene’s solid tumor portfolio and has shown potential across multiple tumor types and disease settings. The global TEVIMBRA clinical development program includes almost 14,000 patients enrolled to date in 34 counties and regions across 66 trials, including 20 registration-enabling studies. TEVIMBRA is approved in more than 42 countries, and more than 1.3 million patients have been treated globally. 

 

About BRUKINSA®(zanubrutinib) 

 

BRUKINSA is an orally available, small molecule inhibitor of Bruton’s tyrosine kinase (BTK) designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues.  

  

BRUKINSA has the broadest label globally of any BTK inhibitor and is the only BTK inhibitor to provide the flexibility of once or twice daily dosing. The global BRUKINSA clinical development program includes about 6,000 patients enrolled in 30 countries and regions across more than 35 trials. BRUKINSA is approved in more than 70 markets, and more than 100,000 patients have been treated globally.  

 

About EVA Pharma 

 

EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind  

 

capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biologic products. 

 

With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies. 

 

Guided by a relentless drive to ensure sustainable access to pressing, yet unmet, disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand. 

 

EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide. 

 

For more information, please visit: www.evapharma.com & https://www.evapharma.com/newsroom or follow us on Facebook, LinkedIn & Instagram   

 

About BeiGene 

 

BeiGene, which plans to change its name to BeOne Medicines Ltd., is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of nearly 11,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn. 

 

Forward-Looking Statements 
 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s ability to deliver transformative therapies to patients with cancer; the potential of  

BRUKINSA® (zanubrutinib) and TEVIMBRA® (tislelizumab) to address critical needs in oncology; the future development, regulatory approvals, and commercial success of BRUKINSA and TEVIMBRA; and BeiGene’s plans, commitments, aspirations, and goals under the heading “About BeiGene.” 

Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its medicines; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approvals; BeiGene’s ability to achieve commercial success for its approved medicines and investigational drug candidates; its ability to obtain and maintain protection of intellectual property; its reliance on third parties to conduct development, manufacturing, commercialization, and other services; its limited experience in  

 

 

obtaining regulatory approvals and commercializing pharmaceutical products; and its ability to obtain additional funding and achieve and maintain profitability. 

 

Additional information is available in BeiGene’s most recent quarterly report on Form 10-Q, as well as subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date hereof, and BeiGene undertakes no duty to update such information unless required by law. 

 

Issued by: 

EVA Pharma, El Sharekat St., El Opera-Abdeen – Cairo - Egypt 
 
BeiGene International GmbH, Dubai Science Park, Al Barsha - Al Barsha South - Dubai - United Arab Emirates. 

Date of Preparation: 

26 March 2025 

* 

References 

1. BRUKINSA® (zanubrutinib) - U.S. Food and Drug Administration. FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. January 19, 2023. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma 

2. TEVIMBRA® (tislelizumab) - U.S. Food and Drug Administration. Drug Trials Snapshots: TEVIMBRA. March 14, 2024. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tevimbra 

3. International Agency for Research on Cancer. GLOBOCAN 2020: Egypt Fact Sheet. World Health Organization; 2021. Available at: https://gco.iarc.who.int/media/globocan/factsheets/populations/818-egypt-fact-sheet.pdf.  Accessed 21 March 2025. 

 

END 

 

For media inquiries contact - BeiGene:  

 

Louise Carter Rosa Soto 

Email: louise.carter@beigene.com Email: rosa.soto@beigene.com 

 

For media inquiries contact – EVA Pharma:  

 

Ahmed Ellewa 

Email: ahmed.ellewa@evapharma.com